What is the price target for PRLD stock?
9 analysts have analysed PRLD and the average price target is 4.08 USD. This implies a price increase of 21.43% is expected in the next year compared to the current price of 3.36.
PRELUDE THERAPEUTICS INC (PRLD) Forecast, Price Target & Analyst Ratings
NASDAQ:PRLD • US74065P1012
Current stock price
3.36 USD
+0.06 (+1.82%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRELUDE THERAPEUTICS INC (PRLD).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 18, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.03
- Revenue Estimate
- 35.7M
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
+ 21.43%
From current price of $3.36 to mean target of $4.08, Based on 9 analyst forecasts
Low
$3.03
Median
$4.08
High
$5.25
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for PRLD. The average price target is 4.08 USD. This implies a price increase of 21.43% is expected in the next year compared to the current price of 3.36.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
PRLD was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about PRLD.
In the previous month the buy percentage consensus was at a similar level.
PRLD was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-18 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-29 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-11 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-19 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-03-13 | JMP Securities | Initiate | Market Outperform |
| 2024-02-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-12-19 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2023-08-04 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-03-17 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-21 | B of A Securities | Downgrade | Neutral -> Underperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 18, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.03
- Revenue Estimate
- 35.7M
- Revenue Q2Q
- 792.50%
- EPS Q2Q
- 92.22%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
PRLD is expected to report earnings on 3/18/2026. The consensus EPS estimate for the next earnings is -0.03 USD and the consensus revenue estimate is 35.70M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7M | -100.00% | 51M | 102M 100.00% | 102M | 102M | 102M | 164.83M 61.60% | 246.76M 49.71% | 335.74M 36.06% | |||
| EBITDA YoY % growth | -122.22M -8.33% | -131.108M -7.27% | -137.942M -5.21% | -170.968M -23.94% | -185.985M -8.78% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -123.54M -8.62% | -132.277M -7.07% | -139.714M -5.62% | -114.369M 18.14% | -27.397M 76.04% | 24.684M 190.10% | 113.42M 359.49% | 43.758M -61.42% | 72.624M 65.97% | -30.6M -142.13% | -31.62M -3.33% | -31.62M | |
| Operating Margin | N/A | N/A | -1,995.91% | N/A | -53.72% | 24.20% | 111.20% | 42.90% | 71.20% | -18.56% | -12.81% | -9.42% | |
| EPS YoY % growth | -2.44 -0.83% | -2.03 16.80% | -1.69 16.75% | -1.27 24.65% | -1.07 15.90% | -0.44 58.71% | -1.22 -176.82% | -0.90 26.67% | -0.53 40.91% | -0.21 59.62% | 0.15 171.43% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.03 92.22% | -0.19 55.07% | -0.19 52.48% | 0.13 150.41% | -0.20 -572.41% | -0.25 -34.05% | -0.22 -14.66% | -0.24 -285.21% | -0.28 -40.00% | -0.28 -10.89% | -0.28 -26.03% | -0.28 -16.81% |
| Revenue Q2Q % growth | 35.7M 792.50% | -100.00% | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 2.125M 106.28% | -19.095M 50.87% | -19.457M 46.39% | 31.437M 253.97% | -19.364M -1,011.23% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.24%
EPS Next 5 Year
7.99%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
268.40%
Revenue Next 5 Year
118.67%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PRELUDE THERAPEUTICS INC / PRLD Forecast FAQ
What is the next earnings date for PRLD stock?
PRELUDE THERAPEUTICS INC (PRLD) will report earnings on 2026-03-18, after the market close.
What are the consensus estimates for PRLD stock next earnings?
The consensus EPS estimate for the next earnings of PRELUDE THERAPEUTICS INC (PRLD) is -0.03 USD and the consensus revenue estimate is 35.70M USD.
How do analysts rate PRELUDE THERAPEUTICS INC (PRLD)?
The consensus rating for PRELUDE THERAPEUTICS INC (PRLD) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.